What is Mounjaro approved to treat?

Mounjaro is FDA-approved to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It was approved on May 13, 2022 as the first dual GIP and GLP-1 receptor agonist. It is not approved for weight loss; the weight-management brand of the same drug is Zepbound.

Is Mounjaro the same drug as Zepbound?

Yes. Mounjaro and Zepbound both contain tirzepatide and are made by Eli Lilly. The difference is the brand and the approved use: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management and obstructive sleep apnea. The chemistry is identical.

How much does Mounjaro cost per month without insurance in 2026?

Mounjaro's list price is about $1,079.77 for a 28-day supply, the same for any strength. Without insurance, people often use Eli Lilly's self-pay tirzepatide vials, which run roughly $349 to $499 a month depending on dose, or pharmacy discount coupons. Prices vary by pharmacy and change frequently.

What dose strengths does Mounjaro come in?

Mounjaro comes in six once-weekly strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg. The 2.5 mg dose is a four-week starter used to reduce nausea, not a treatment dose. A clinician steps the dose up by 2.5 mg about every four weeks as tolerated, up to a maximum of 15 mg.

How is Mounjaro injected and how often?

Mounjaro is a subcutaneous injection given once a week, on the same day each week, into the abdomen, thigh, or upper arm. It is supplied as cartons of four prefilled, single-dose pens, one per weekly dose. Its long half-life of about five days is what allows weekly dosing.

Can I use Mounjaro for weight loss?

Mounjaro is not FDA-approved for weight loss; the approved weight brand of the same drug, tirzepatide, is Zepbound. A clinician may prescribe Mounjaro off-label in some cases, but insurance usually will not cover it for weight, so people often pay cash or pursue Zepbound instead.

Is the Mounjaro shortage over in 2026?

Yes. The FDA determined the tirzepatide shortage resolved in 2024 and reaffirmed it with a declaratory order on December 19, 2024, so Mounjaro is generally available through normal pharmacies again. Individual stores can still have brief gaps, and the resolution wound down the legal basis for compounded copies.

Is there a generic or compounded Mounjaro?

No FDA-approved generic Mounjaro exists; tirzepatide is still under patent. Compounded tirzepatide is no longer broadly legal now that the shortage is over, with compounding transition windows that closed in early 2025. Products sold as research-use-only or compounded tirzepatide are not FDA-verified for identity, dose, or sterility.

How long does Mounjaro stay in your system?

Tirzepatide has a half-life of roughly five days, which is why one injection lasts a week. As a rough rule, a drug is mostly cleared after about five half-lives, so tirzepatide takes several weeks to leave the body after the last dose. Individual timing varies, so ask your clinician.

A modern once-weekly auto-injector pen and a single-dose vial resting on a clean white clinical counter beside a blood-glucose meter under soft daylight.

Mounjaro, Decoded: Tirzepatide's Diabetes Brand — Cost, Access & Why It Isn't Just "Another Ozempic"

Q: Did Mounjaro beat Ozempic in trials?

In SURPASS-2, a 40-week head-to-head trial published in 2021, tirzepatide 15 mg lowered A1c by about 2.46 percentage points versus about 1.86 for semaglutide 1 mg, with greater weight loss. These are trial results in people with type 2 diabetes, not a guarantee of individual outcomes.

Aurélie Rondon, Ph.D.Reviewed by Prof. Joanna Trylska, Ph.D.

Updated 2026-06-15T00:00:00.000Z16 min read · 4,282 words

Mounjaro is Eli Lilly's brand name for a once-weekly type 2 diabetes injection, and the drug inside it, tirzepatide, is genuinely different from the molecule in Ozempic. Where Ozempic's semaglutide works on a single gut-hormone receptor, tirzepatide works on two at once. That one design choice is the reason Mounjaro is not simply "another Ozempic," and it is the thread that runs through everything else on this page. The same molecule, branded Zepbound, is also one of the most-used peptides for weight loss.

This is the brand and market hub for Mounjaro. It answers the practical questions people actually search for: what Mounjaro is as a product, why its dual-receptor action sets it apart from Ozempic, how its diabetes trial results stack up, how much it costs in 2026, whether insurance covers it, which dose strengths and pens it comes in, how it differs from Zepbound, and whether the shortage is over. For the deep pharmacology of the molecule itself, including the full mechanism and complete dosing science, we keep things brief here and point you to the tirzepatide molecule guide. The goal is one clear map of the Mounjaro brand.

Key Takeaways

Mounjaro is Eli Lilly's brand of tirzepatide for type 2 diabetes, FDA-approved on May 13, 2022 as the first medicine to activate both the GIP and GLP-1 receptors (Eli Lilly, PR Newswire, 2022).

It is a dual agonist, not a single one like Ozempic. Tirzepatide hits two incretin receptors (GIP plus GLP-1), while semaglutide hits one (GLP-1), which is the core reason the two drugs behave differently (NCBI StatPearls, 2024).

In a head-to-head diabetes trial it outperformed semaglutide. In SURPASS-2, tirzepatide 15 mg lowered A1c by about 2.46 percentage points versus about 1.86 for semaglutide 1 mg, with greater weight loss (NEJM via Eli Lilly, 2021).

The list price is about $1,079.77 for a 28-day supply regardless of strength, but most people pay far less through insurance, a Lilly savings card, or self-pay vials (GoodRx, 2026).

Mounjaro and Zepbound are the same molecule in different brands: Mounjaro for diabetes, Zepbound for weight management and sleep apnea. Picking between them is about indication and coverage, not chemistry (Eli Lilly, 2022).

The shortage is over. The FDA confirmed the tirzepatide shortage resolved and issued a reaffirming declaratory order on December 19, 2024, which also wound down the legal basis for compounded copies (BioPharma Dive, 2024).

Why isn't Mounjaro just another Ozempic?

Because Mounjaro's drug acts on two gut-hormone receptors at once, while Ozempic's acts on only one, which is the single biggest reason the two medicines are not interchangeable. They belong to the same broad family but are built differently.

Mounjaro contains tirzepatide, a "dual agonist" that switches on both the GIP receptor and the GLP-1 receptor. Ozempic contains semaglutide, a "single agonist" that switches on the GLP-1 receptor alone. Both receptors are part of the body's incretin system, which nudges insulin out at the right time, slows the stomach, and dials down appetite. Adding GIP to the mix is what makes tirzepatide a structurally newer kind of drug rather than a copy of an older one (NCBI StatPearls, 2024).

That difference is not just academic. Because tirzepatide engages a second pathway, it has produced larger blood-sugar and weight reductions than semaglutide in head-to-head testing, which we cover below. The deep mechanism, how each receptor signals inside the cell, lives on the molecule hub; here, the takeaway is that "dual versus single" is the honest one-line answer to why Mounjaro is its own thing. For the receptor-level science, see the tirzepatide molecule guide, and for the semaglutide side, the semaglutide guide.

Mounjaro's tirzepatide engages two incretin receptors; Ozempic's semaglutide engages one.

What is Mounjaro and who makes it?

Mounjaro is Eli Lilly's brand name for once-weekly injectable tirzepatide, a dual GIP and GLP-1 receptor agonist FDA-approved to lower blood sugar in adults with type 2 diabetes. It is a once-a-week shot you give yourself under the skin.

Eli Lilly, the American pharmaceutical company, developed and manufactures tirzepatide and is the only maker of the FDA-approved versions. Mounjaro was the first product to carry the molecule, and the company later launched the same drug under a second brand, Zepbound, for weight management. So Mounjaro and Zepbound are siblings from one manufacturer, not rival drugs from competing companies.

The drug itself is a once-weekly injection because tirzepatide has a long half-life of roughly five days, letting a single dose cover the week. Mounjaro is simply the diabetes-branded, diabetes-dosed package of that molecule. For what GIP and GLP-1 peptides are and how they signal at the receptor level, see how peptides work in the body and the full profile in the tirzepatide molecule guide.

A close-up of a single once-weekly auto-injector pen and a small clear single-dose vial on a clean white clinical surface, soft studio light, shallow depth of field, no text or logos.

Citation capsule. Mounjaro is Eli Lilly's brand of injectable tirzepatide, the first FDA-approved dual GIP and GLP-1 receptor agonist, approved on May 13, 2022 to improve blood sugar in adults with type 2 diabetes alongside diet and exercise. Source: Eli Lilly / PR Newswire, "FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes," 2022.

How well does Mounjaro work for diabetes?

In its SURPASS trial program, Mounjaro produced large drops in A1c and, in a direct comparison, beat Ozempic's semaglutide on both blood sugar and weight. These are diabetes-control results, the job Mounjaro is actually approved for.

The clearest single data point comes from SURPASS-2, a 40-week head-to-head trial against semaglutide published in the New England Journal of Medicine in 2021. At the top 15 mg dose, tirzepatide lowered A1c by about 2.46 percentage points, compared with about 1.86 points for semaglutide 1 mg, and it produced greater weight loss of roughly 12.4 kg (about 27 lb) over the trial (NEJM via Eli Lilly, 2021). Across the broader SURPASS program, a large majority of participants reached an A1c below the 7% target.

A practical note on framing: these are figures studied in clinical trials, not a promise of personal results, and the weight loss seen in diabetes trials is a secondary outcome rather than Mounjaro's approved purpose. The deep trial-by-trial breakdown and the weight-loss results that belong to the Zepbound story live elsewhere; here we keep it to the diabetes headline. For the full results picture, see the tirzepatide molecule guide.

In a direct trial, every tirzepatide dose cut A1c more than semaglutide 1 mg did.

Mounjaro vs Ozempic vs Zepbound: how do they differ?

Mounjaro and Ozempic are different molecules (dual-agonist tirzepatide versus single-agonist semaglutide), while Mounjaro and Zepbound are the same molecule in two brands, one for diabetes and one for weight. Sorting them out is the question most people really have.

Here is the brand-level map. Mounjaro (tirzepatide) is a weekly diabetes injection that targets two receptors. Ozempic (semaglutide) is a weekly diabetes injection that targets one. Zepbound is tirzepatide again, the very same drug as Mounjaro, but branded and approved for chronic weight management and obstructive sleep apnea instead of diabetes. So if you are comparing Mounjaro to Ozempic, you are comparing two molecules; if you are comparing Mounjaro to Zepbound, you are comparing two labels on one molecule.

Brand	Active drug	Receptors	FDA-approved use	Dose range
Mounjaro	Tirzepatide	GIP + GLP-1 (dual)	Type 2 diabetes	2.5 to 15 mg
Ozempic	Semaglutide	GLP-1 only (single)	Type 2 diabetes; CV and kidney risk	0.25 to 2 mg
Zepbound	Tirzepatide	GIP + GLP-1 (dual)	Weight management; sleep apnea	2.5 to 15 mg

Because the active drug in Mounjaro and Zepbound is identical, the practical choice between them comes down to your diagnosis and what your insurance will cover, not the chemistry. The deeper head-to-head comparisons belong in their own articles: see Mounjaro vs Ozempic for the dual-versus-single matchup and the Zepbound guide for the weight-brand side.

What dose strengths and pens does Mounjaro come in?

Mounjaro comes in six once-weekly strengths, 2.5, 5, 7.5, 10, 12.5, and 15 mg, with 2.5 mg used only as a four-week starter to limit nausea, not as a treatment dose. Each strength is a separate pen, so the one you carry depends on where you are in the schedule.

The standard plan is a slow climb, called titration. A clinician almost always starts at 2.5 mg once weekly for four weeks, then steps up by 2.5 mg roughly every four weeks as tolerated, up to a maximum of 15 mg (Drugs.com, 2026). That gradual increase is what keeps the mostly digestive side effects manageable; the starter dose is deliberately too low to do much for blood sugar and exists only to let your body adjust.

Mounjaro is supplied as cartons of four prefilled, single-dose pens, one for each weekly injection in a month. Lilly has also offered tirzepatide in single-dose vials through its direct self-pay channel, which is the same drug in a different container. The full week-by-week titration logic and missed-dose handling live in the molecule guide, so we keep it brand-level here. See the tirzepatide molecule guide for the complete dosing science and the peptide injection guide for technique.

How much does Mounjaro cost in 2026?

Mounjaro's list price is about $1,079.77 for a 28-day supply regardless of strength, but few people pay that; with commercial insurance plus a Lilly savings card it can drop to as little as about $25 a month, and self-pay vials run roughly $349 to $499. What you actually pay depends on insurance, pharmacy, and which program you use.

There are several prices worth separating, because they get confused constantly:

List price (WAC): about $1,079.77 for a 28-day supply, the same for any strength (GoodRx, 2026). This is the sticker price, not what most people pay.
With commercial insurance plus a Lilly savings card: eligible, commercially insured patients may pay as little as about $25 a month through Eli Lilly's Mounjaro savings program (confirm current eligibility and term limits on the official savings page).
Self-pay tirzepatide vials (LillyDirect): roughly $349 to $499 a month for cash-pay patients buying single-dose vials of the drug directly, depending on dose (GoodRx, 2026).
Discount-card retail (GoodRx-style): cash coupons typically land somewhere below the full list price but still in the high hundreds to about a thousand dollars, varying widely by pharmacy (GoodRx, 2026).

Because these prices move and depend on eligibility, treat them as a 2026 snapshot rather than a quote, and confirm the current figure with the pharmacy or Lilly. The tirzepatide molecule guide tracks the full pricing and access breakdown.

The gap between Mounjaro's sticker price and what people actually pay is large, and depends entirely on coverage.

What are the main side effects and warnings?

Mounjaro's most common side effects are gastrointestinal, mainly nausea, diarrhea, vomiting, constipation, and reduced appetite, and they tend to flare right after each dose increase and then settle. It also carries a serious boxed warning you should know before starting.

The digestive effects are by far the most common and are usually worst in the days after a dose step-up, which is exactly why the schedule climbs slowly. Most people find the nausea eases as the body adapts, and the slow titration is the main tool for keeping it tolerable. Less common but more serious risks reported with tirzepatide include pancreatitis, gallbladder problems, low blood sugar when combined with insulin or sulfonylureas, kidney injury from dehydration, and allergic reactions (Drugs.com, 2026).

The headline safety item is the boxed warning for a risk of thyroid C-cell tumors, based on rodent studies, which makes Mounjaro contraindicated in people with a personal or family history of medullary thyroid carcinoma or the MEN 2 syndrome (NCBI StatPearls, 2024). This is a brand-level summary, not the full safety playbook; the complete side-effect management guide, including what to do when nausea spikes, lives in the tirzepatide molecule guide.

How do you get Mounjaro?

You get Mounjaro with a prescription from a licensed clinician for type 2 diabetes, filled at a pharmacy; you can start in person or through a reputable telehealth service, but the legitimate route always ends with genuine, pharmacy-dispensed product. There is a clear path and a risky shortcut.

The legitimate path looks like this:

See a clinician (primary care, an endocrinologist, or a vetted telehealth provider) who confirms you are an appropriate candidate, typically for type 2 diabetes.
Get a prescription for Mounjaro at the starting 2.5 mg dose.
Fill it at a licensed pharmacy, retail or through Lilly's direct channel, which dispenses genuine, quality-controlled pens or vials.
Sort out cost using insurance, the Lilly savings card, or the self-pay vial program before you commit to a long course.
Follow the titration plan your clinician sets, stepping up by 2.5 mg about every four weeks to limit side effects.

The shortcut to avoid is buying product labeled "research use only," "compounded," or shipped from overseas sellers. With the shortage resolved, those are no longer a legal or quality-verified option, and you cannot confirm what is inside. For the broader rules on legality, see are peptides legal, and for technique, the peptide injection guide.

A bright, modern pharmacy pickup counter with a pharmacist's hand passing a small medication carton to a patient, warm natural light, clean and professional, no readable text or logos.

Is Mounjaro covered by insurance or Medicare?

Many commercial plans and Medicare Part D cover Mounjaro for type 2 diabetes, usually with a prior authorization, because diabetes is its approved use; coverage for weight loss is a different and harder story. The diagnosis on the prescription is what drives approval.

For people with type 2 diabetes, Mounjaro is widely included on formularies, though plans frequently require a prior authorization or step therapy first. That is because diabetes is exactly what the brand is approved to treat, so the request lines up with the label. The friction shows up when the goal is weight: Mounjaro is not approved for weight loss, and by federal law Medicare cannot cover a drug used only for weight loss, which is the single biggest reason people end up paying cash or switching to a discussion about Zepbound.

The honest practical rule for 2026 is straightforward: if you have type 2 diabetes, Mounjaro is often coverable with paperwork; if you do not, expect to pay out of pocket or look at the on-label weight brand instead. Coverage rules change often, so confirm your specific plan. The weight-brand coverage picture lives in the Zepbound guide.

Is the Mounjaro shortage over?

Yes. The FDA confirmed the tirzepatide shortage resolved in 2024 and reaffirmed it with a declaratory order on December 19, 2024, so Mounjaro is generally available again through normal pharmacy channels. The end of the shortage also changed the rules for compounded copies.

Through 2023 and into 2024, surging demand for tirzepatide outstripped supply, and Mounjaro spent stretches on the FDA's drug-shortage list. After Lilly expanded manufacturing, the FDA determined the shortage was resolved; following a legal challenge, the agency reaffirmed that decision in December 2024 (BioPharma Dive, 2024). Pharmacies can again order standard doses, though individual stores can still have brief gaps.

The resolution had a second effect. During a shortage, pharmacies may compound copies of a scarce drug; once the shortage ended, that legal basis wound down, with transition windows of roughly 60 days for state-licensed pharmacies and 90 days for outsourcing facilities (Foley & Lardner, 2024). That is why broadly marketed "compounded tirzepatide" lost its footing heading into 2025.

Our take: The end of the shortage was good news for legitimate supply but removed the cheap compounded route many people had leaned on. If your budget depended on a low-cost compounded vial, the realistic 2026 options are insurance plus a Lilly savings card, the self-pay vial program, or a clinician's help with coverage, not a "research" vial of unknown contents. For how to evaluate any peptide's paperwork, see are peptides legal.

What does our community usage data show?

Within the ProtocolPlus community, tirzepatide (the drug in Mounjaro) is the single most-tracked compound, and members typically finish a multi-dose vial in about three weeks, consistent with once-weekly use. These are usage-pattern figures from our app, labeled as community signal, not a clinical or stability claim.

In our anonymized tracking data, tirzepatide accounts for the largest share of activity of any compound: 52,400 logged doses from 8,384 tracking users, drawn from a global window of 27,272 unique trackers and 233,668 logged doses (data window September 2024 to June 2026). That works out to roughly 22% of all logged doses in the community. The median vial runs about 22 days from first to last logged dose, clustering around the three-week mark that mirrors weekly dosing. As with all our app data, these numbers describe how people use the compound, not how long it is chemically stable.

Tirzepatide is the most-tracked compound in our community, a usage signal that mirrors Mounjaro and Zepbound's real-world popularity.

Frequently Asked Questions

No. Mounjaro contains tirzepatide, a dual agonist that activates two receptors (GIP and GLP-1), while Ozempic contains semaglutide, a single agonist that activates only GLP-1. They are different molecules from different makers, Eli Lilly and Novo Nordisk, even though both are once-weekly diabetes injections.

The bottom line

Mounjaro is the diabetes-branded face of tirzepatide, Eli Lilly's once-weekly injection approved to control blood sugar in adults with type 2 diabetes. The reason it is not just "another Ozempic" comes down to one design choice: tirzepatide is a dual GIP and GLP-1 agonist, while Ozempic's semaglutide hits only GLP-1, and that difference showed up as larger A1c and weight reductions when the two were tested head to head. Its sibling Zepbound is the very same molecule wearing a weight-loss label.

If you take away one idea, make it this: with Mounjaro, the molecule is settled and approved, so the real decisions are about brand, indication, and cost. Match the brand to the approved use, confirm coverage before you start, and get the genuine product through a licensed pharmacy. From here, the natural next steps are the tirzepatide molecule guide, the Mounjaro vs Ozempic comparison, and the Zepbound guide. And for anything you might consider, talk to a qualified clinician first.

Sources

Eli Lilly / PR Newswire. "FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes." 2022. Retrieved 2026-06-15. https://www.prnewswire.com/news-releases/fda-approves-novel-dual-targeted-treatment-for-type-2-diabetes-301547265.html
Eli Lilly / Investor Relations. "Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes." 2021. Retrieved 2026-06-15. https://investor.lilly.com/news-releases/news-release-details/lillys-surpass-2-results-published-new-england-journal-medicine
NCBI Bookshelf / StatPearls. "Tirzepatide." 2024. Retrieved 2026-06-15. https://www.ncbi.nlm.nih.gov/books/NBK585056/
Drugs.com. "Mounjaro (tirzepatide) FDA Approval History." 2026. Retrieved 2026-06-15. https://www.drugs.com/history/mounjaro.html
Drugs.com. "Mounjaro: Uses, Dosage, Side Effects & Warnings." 2026. Retrieved 2026-06-15. https://www.drugs.com/mounjaro.html
GoodRx. "Mounjaro Prices, Coupons & Savings Tips." 2026. Retrieved 2026-06-15. https://www.goodrx.com/mounjaro
BioPharma Dive. "Zepbound, Mounjaro shortages are resolved, FDA confirms." 2024. Retrieved 2026-06-15. https://www.biopharmadive.com/news/fda-tirzepatide-shortage-resolved-lilly-zepbound-compounding/736020/
Foley & Lardner. "GLP-1 Drugs: FDA Re-Confirms Decision Removing Tirzepatide from the Drug Shortage List." 2024. Retrieved 2026-06-15. https://www.foley.com/insights/publications/2024/12/glp-1-drugs-fda-removing-tirzepatide-drug-shortage-list/